Drugs@FDA: FDA-Approved Drugs
Biologic License Application (BLA): 125521
Company: ELI LILLY AND CO
Company: ELI LILLY AND CO
Drug Name | Active Ingredients | Strength | Dosage Form/Route | Marketing Status | TE Code | RLD | RS |
---|---|---|---|---|---|---|---|
TALTZ | IXEKIZUMAB | 80MG/ML | INJECTABLE;INJECTION | Prescription | None | No | No |
Original Approvals or Tentative Approvals
Action Date | Submission | Action Type | Submission Classification | Review Priority; Orphan Status | Letters, Reviews, Labels, Patient Package Insert | Notes | Url |
---|---|---|---|---|---|---|---|
03/22/2016 | ORIG-1 | Approval | N/A |
Label (PDF)
Letter (PDF) Review Summary Review (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125521s000lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2016/125521Orig1s000ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/125521Orig1s000TOC.cfm https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/125521Orig1s000SumR.pdf |
Supplements
Action Date | Submission | Supplement Categories or Approval Type | Letters, Reviews, Labels, Patient Package Insert | Note | Url |
---|---|---|---|---|---|
08/20/2024 | SUPPL-32 | Supplement |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/125521s032lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/125521Orig1s032ltr.pdf | |
11/20/2023 | SUPPL-31 | Supplement |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/125521Orig1s031lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/125521Orig1s031ltr.pdf | |
09/13/2023 | SUPPL-28 | Supplement |
Letter (PDF)
|
Label is not available on this site. |
https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/125521Orig1s028ltr.pdf |
07/27/2022 | SUPPL-24 | Supplement |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125521s024lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/125521Orig1s024ltr.pdf | |
05/04/2022 | SUPPL-23 | Supplement |
Label is not available on this site. |
||
03/26/2020 | SUPPL-20 | Supplement |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125521s020lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/125521Orig1s020ltr.pdf | |
05/29/2020 | SUPPL-19 | Supplement |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125521s019lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/125521Orig1s019ltr.pdf | |
08/23/2019 | SUPPL-16 | Supplement |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125521s016lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/125521Orig1s016ltr.pdf | |
03/10/2021 | SUPPL-14 | Supplement |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125521s014lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/125521Orig1s014ltr.pdf | |
03/16/2018 | SUPPL-11 | Supplement |
Letter (PDF)
|
Label is not available on this site. |
https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/125521Orig1s011ltr.pdf |
05/17/2018 | SUPPL-9 | Supplement |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125521s009lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/125521Orig1s009ltr.pdf | |
12/01/2017 | SUPPL-4 | Supplement |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125521s004lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/125521Orig1s004ltr.pdf | |
07/05/2017 | SUPPL-3 | Supplement |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125521s003lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/125521Orig1s003ltr.pdf | |
04/19/2018 | SUPPL-2 | Supplement |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125521Orig1s002lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/125521Orig1s002ltr.pdf |
Action Date | Submission | Supplement Categories or Approval Type | Letters, Reviews, Labels, Patient Package Insert |
Note | Url |
---|---|---|---|---|---|
08/20/2024 | SUPPL-32 | Labeling-Package Insert | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/125521s032lbl.pdf | |
08/20/2024 | SUPPL-32 | Labeling-Medication Guide | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/125521s032lbl.pdf | |
11/20/2023 | SUPPL-31 | Tentative Approval | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/125521Orig1s031lbl.pdf | |
07/27/2022 | SUPPL-24 | Labeling-Package Insert | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125521s024lbl.pdf | |
07/27/2022 | SUPPL-24 | Labeling-Medication Guide | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125521s024lbl.pdf | |
03/10/2021 | SUPPL-14 | Labeling-Package Insert | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125521s014lbl.pdf | |
05/29/2020 | SUPPL-19 | Efficacy-New Indication | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125521s019lbl.pdf | |
03/26/2020 | SUPPL-20 | Efficacy-New Patient Population | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125521s020lbl.pdf | |
08/23/2019 | SUPPL-16 | Efficacy-New Indication | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125521s016lbl.pdf | |
05/17/2018 | SUPPL-9 | Efficacy-Labeling Change With Clinical Data | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125521s009lbl.pdf | |
04/19/2018 | SUPPL-2 | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125521Orig1s002lbl.pdf | ||
12/01/2017 | SUPPL-4 | Efficacy-New Indication | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125521s004lbl.pdf | |
07/05/2017 | SUPPL-3 | Labeling-Package Insert | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125521s003lbl.pdf | |
03/22/2016 | ORIG-1 | Approval | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125521s000lbl.pdf |